Brilinta
Brilinta is a medication containing Ticagrelor, primarily used as an antiplatelet agent to prevent blood clots. It is often prescribed for patients who have experienced acute coronary syndrome or have a history of heart attacks. This medication works by inhibiting platelet activation and aggregation, reducing the risk of future cardiovascular events. Brilinta is available in tablet form and is usually taken orally. It is important for users to adhere to their prescribed dosage schedule to maintain its efficacy. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.Active substance:
TicagrelorPharmachologic effect:
Brilinta (Ticagrelor) is an antiplatelet medication that inhibits platelet aggregation by reversibly binding to the P2Y12 receptor, preventing ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby reducing the risk of thrombotic cardiovascular events.Indications:
- Prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
Contraindications:
- Hypersensitivity to Ticagrelor or any of the excipients
- Active pathological bleeding
- History of intracranial hemorrhage
- Severe hepatic impairment
Side effects:
In order of decreasing probability: Dyspnea, Bleeding, Nausea, Diarrhea, Dizziness, Headache, Increased uric acid levels, Bradycardia
Dosing and Administration:
The recommended dose of Brilinta is 90 mg twice daily. Treatment should be initiated with a single 180 mg loading dose. Brilinta can be taken with or without food.
Storage:
Store at a temperature not exceeding 30°C (86°F).
Brilinta
in Cyrillic : Брилинта
SUBSTANCE
Ticagrelor
DOSAGE FORM
tablets
